New York, NY – May 2, 2012 - Royalty Pharma announced today that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash. The Fumapharm earn-out primarily represents an indirect interest in Biogen Idec’s BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of relapsing-remitting multiple sclerosis (RRMS).
New York, NY and South San Francisco, CA – March 29, 2012 - Royalty Pharma and Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis’ lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.
New York, NY – February 29, 2012 - Royalty Pharma announced today that it has acquired certain rights to receive royalties on future worldwide net sales of Cimzia® and Mircera® for an aggregate cash payment of $124 million.
San Francisco, CA – February 29, 2012 - Nektar Therapeutics (Nasdaq: NKTR) today announced that it agreed to sell to Royalty Pharma its royalties on future sales of CIMZIA®, under Nektar's agreement with UCB Pharma, and MIRCERA®, under Nektar's agreement with Roche. In consideration for the sale, Royalty Pharma will pay Nektar an aggregate cash payment of $124.0 million.
New York, NY - September 07, 2011 - Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully refinanced $2.75 billion of outstanding debt and funded a one-time $850 million cash distribution to shareholders.
Boston, MA – August 11, 2011 - Arisaph Pharmaceuticals, Inc. (“Arisaph”) and Royalty Pharma announced today the closing of a transaction valued up to $26.25 million.
Tokyo - June 30, 2011 - Astellas Pharma Inc. announced today that Prosidion’s patent estate and associated royalty stream relating to the use of dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes has been sold to Royalty Pharma for a total cash payment of $609 million. The transaction is expected to close in July 2011.
New York, NY - May 18, 2011 - Royalty Pharma is pleased to announce that George Lloyd has joined the company as Executive Vice President, Investments.
New York, NY - April 4, 2011 - Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million.
San Diego, CA and New York, NY, December 15, 2010 - Cypress Bioscience, Inc. (Nasdaq: CYPB) (“Cypress”), a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, announced today that it has entered into a definitive merger agreement with Ramius V&O Acquisition LLC, an affiliate of Ramius LLC (collectively, “Ramius”) and affiliates of Royalty Pharma (“Royalty Pharma”), providing for the acquisition of Cypress by Ramius and Royalty Pharma.
New York, NY, December 7, 2009 - Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations.
New York, NY, July 8, 2008 - Royalty Pharma is pleased to announce that James Reddoch, PhD, has joined the company as Executive Vice President, Head of Research.
New York, NY, April 23, 2008 - The Children’s Hospital Foundation, the parent company of The Children’s Hospital of Philadelphia® (CHOP) and Royalty Pharma announced today that the Foundation has sold its worldwide royalty interest in respect of sales of RotaTeq® from and after October 1, 2007, to Royalty Pharma for $182 million in cash.
New York, NY, December 18, 2007 - Royalty Pharma and Northwestern University announced today that Northwestern has sold a portion of its worldwide royalty interest in Lyrica® to Royalty Pharma for $700 million in cash.
New York, NY, May 4, 2007 - Royalty Pharma and New York University (NYU) announced today that NYU has sold a portion of NYU’s worldwide royalty interest in Remicade® to Royalty Pharma.
New York, NY, October 26, 2006 - Royalty Pharma announced today that it has completed the purchase of the rights to a pre-existing royalty interest in HUMIRA® currently held by AstraZeneca plc’s subsidiary, Cambridge Antibody Technology Limited (CAT).
Jumbo $525 Million Royalty Rights Payment Captures Wall Street’s Attention
New York, NY - January 16, 2006 - Wall Street is rubbing its hands in anticipation of more to come after Emory University’s groundbreaking deal to sell the royalty rights for an HIV drug developed by school researchers. Gilead Sciences and Royalty Pharma paid a whopping $525 million for the rights, the largest lump-sum royalty payment to a US university to date.
New York, NY, August 22, 2005 - Royalty Pharma and Memorial Sloan-Kettering Cancer Center ("MSKCC") announced today that they have completed the sale of a portion of MSKCC’s royalty interest in Neupogen® and Neulasta® worldwide for all countries except the United States, China, Japan, South Korea, North Korea and Taiwan.
Foster City, CA, New York, NY, and Atlanta, GA, July 18, 2005 - Gilead Sciences, Inc. (Nasdaq: GILD) and Royalty Pharma today announced that the companies have entered into an agreement with Emory University providing for the purchase of the royalty interest owed to Emory for emtricitabine, also known as Emtriva®. Under the terms of the agreement, Gilead and Royalty Pharma will make a one-time cash payment of $525 million to Emory in exchange for elimination of the emtricitabine royalties due to Emory on worldwide net sales of the product.
Royalty Pharma Accelerates and Increases Royalty Purchase to $32.5 Million as Substitute for Final Two Options
San Diego, CA, and New York, NY, November 9, 2004 - Ligand Pharmaceuticals (Nasdaq: LGND) and Royalty Pharma have amended their royalty agreement for three selective estrogen receptor modulator (SERM) products nearing final stages of development, the companies announced today.
New York, NY, January 22, 2004 - Royalty Pharma acquired a portion of Memorial Sloan-Kettering Cancer Center’s (MSKCC) US royalty interest in Neupogen/Neulasta, the entities announced today. Under the agreement, MSKCC received $263 million in cash up-front plus certain additional payments should Neupogen/Neulasta yearly sales exceed certain agreed sales hurdles. In addition, as part of the agreement, MSKCC has made a $7 million investment in Royalty Pharma.
Royalty Pharma Exercises a $12.5 Million Option on October 1
San Diego, CA, and New York, NY - October 2, 2003 - Ligand Pharmaceuticals (Nasdaq: LGND) and Royalty Pharma have amended their royalty agreement for three selective estrogen receptor modulator (SERM) products nearing completion of Phase III development, the companies announced today.
Approximately $225 Million of Asset-Backed Securities Rated Aaa.
New York - July 30, 2003 - Moody's Investors Service has assigned a rating of Aaa to the $225,000,000 asset-backed note issued by Royalty Pharma Finance Trust (RPFT). The notes are backed initially by a pool of royalty interests and contingent pay rights in thirteen biopharmaceutical products. This is the first time Moody's has assigned a term rating to a transaction backed by biopharmaceutical royalty interests.
San Diego, CA, and New York, NY (BUSINESS WIRE) - January 6, 2003 - Ligand to use increased proceeds of up to $15.4 million through 2003 to accelerate development of Targretin Capsules in NSCLC monotherapy and Targretin Gel in hand dermatitis
September 18, 2002
San Diego, CA - April 18, 2002
Payments of up to $56 Million Enable Additional Investments in R&D 2002-2004
San Diego, CA, March 6, 2002 - Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announced today an agreement with Royalty Pharma AG, which has purchased rights to a share of future payments from Ligand’s collaborative partners’ sales of three selective estrogen receptor modulator (SERM) products now in Phase III development.
Rockville, MD - August 8, 2001
Berkeley, CA - January 8, 1998